Arcus Biosciences, Inc. (RCUS)
NYSE·Healthcare·Biotechnology
$24.60
-1.40%
Mkt Cap $2.47B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 25, 2026 | $35.71M | $33.00M | -7.59% | -$1.11 | -$0.89 | +19.82% | — | — |
| Q4 2025 Oct 28, 2025 | $24.94M | $26.00M | +4.26% | -$1.33 | -$1.27 | +4.51% | — | — |
| Q3 2025 Aug 6, 2025 | $32.48M | $160.00M | +392.58% | -$1.14 | -$0.08 | +93.41% | — | — |
| Q2 2025 May 6, 2025 | $37.36M | $28.00M | -25.05% | -$1.02 | -$1.14 | -11.76% | — | — |
| Q1 2025 Feb 25, 2025 | $29.38M | $26.00M | -11.49% | -$1.17 | -$1.03 | +11.97% | — | — |
| Q4 2024 Nov 6, 2024 | $32.06M | $48.00M | +49.71% | -$1.07 | -$1.00 | +6.54% | — | — |
| Q3 2024 Aug 8, 2024 | $25.61M | $39.00M | +52.28% | -$1.02 | -$1.02 | +0.00% | — | — |
| Q2 2024 May 8, 2024 | $35.56M | $145.00M | +307.76% | -$0.97 | -$0.05 | +94.85% | — | — |
| Q1 2024 Feb 21, 2024 | $28.19M | $31.00M | +9.97% | -$1.09 | -$1.08 | +0.92% | — | — |
| Q4 2023 Nov 7, 2023 | $28.33M | $32.00M | +12.95% | -$1.12 | -$0.94 | +16.07% | — | — |
| Q3 2023 Aug 7, 2023 | $30.30M | $29.00M | -4.29% | -$1.00 | -$1.04 | -4.00% | — | — |
| Q2 2023 May 9, 2023 | $24.97M | $25.00M | +0.12% | -$1.06 | -$1.09 | -2.83% | — | — |
| Q1 2023 Feb 28, 2023 | $23.72M | $345.00K | -98.55% | -$0.99 | -$0.93 | +6.06% | — | — |
| Q4 2022 Nov 2, 2022 | $22.16M | $33.58M | +51.56% | -$1.05 | -$0.90 | +14.29% | — | — |
| Q3 2022 Aug 3, 2022 | $21.57M | $26.76M | +24.05% | -$0.93 | -$0.93 | +0.00% | — | — |
| Q2 2022 May 9, 2022 | $27.21M | $18.00M | -33.84% | $0.83 | -$0.96 | -215.66% | — | — |
| Q1 2022 Feb 23, 2022 | $11.85M | $354.50M | +2891.55% | -$0.74 | $3.71 | +601.35% | — | — |
| Q4 2021 Nov 8, 2021 | $9.37M | $9.46M | +0.97% | -$1.13 | -$1.11 | +1.77% | — | — |
| Q3 2021 Aug 5, 2021 | $12.61M | $9.46M | -24.97% | -$0.77 | -$1.09 | -41.56% | — | — |
| Q2 2021 May 5, 2021 | $12.74M | $9.46M | -25.74% | -$0.71 | -$1.08 | -52.11% | — | — |